ACT UP. Undated. “Candidate Gore Zaps.” http://www.actupny.org/actions/gorezaps.html. AIDS.gov. 2014. “Global AIDS Overview.” . Amfar.org. 2014. “Thirty Years of HIV/AIDS: Snapshots of an Epidemic.” http://www.amfar.org/Thirty-Years-of-HIV/AIDS-Snapshots-of-an-Epidemic/. “Amsterdam Statement to WTO Member States on Access to Medicine.” 1999. http://www.cptech.org/ip/health/amsterdamstatement.html. The Antiretroviral Therapy Cohort Collaboration. 2008. “Life Expectancy of Individuals on Combination Antiretroviral Therapy in High-Income Countries: A Collaborative Analysis of Cohort Studies.” The Lancet, 372: 9635, pp. 293-9. Avafia, Tenu and Savita Narasimhan. 2006. “The TRIPS Agreement and Access to ARVs.” United Nations Development Programme. Avafia, Tenu, Jonathan Berger, and Trudi Hartzenberg. 2006. “The ability of select African countries to utilize TRIPS flexibilities and competition law to ensure a sustainable supply of essential medicines: A study of producing and importing countries.” AVERT. 2014. “Generic Antiretroviral Drugs.” . AVERT. 2014. “History of HIV and AIDS.” . AVERT. 2014(b). “Antiretroviral Drug Prices.” AVERT. 2014(c). “HIV/AIDS, TRIPS, and Second-Line Therapy.” . AVERT. 2014(d). “HIV & AIDS in Botswana.” AVERT. 2014(e). “History of HIV & AIDS in South Africa.” AVERT. 2014(f). “HIV & AIDS in South Africa.” 2014(g). “HIV & AIDS in Uganda.” www.avert.org/hiv-aids-uganda.htm. Barton, John. 2001. “Differentiated Prices of Patented Products.” Indian Council for Research on International Economic Relations.” .
Merck. 2010. “Merck Provides New Funding to Fight HIV/AIDS in Botswana.” Merck. 2011. “Public Policy Statement: Intellectual Property and Access to Medicines in the Developing World.” Merck. 2014. “ACHAP.” enjamin Coriat, Yves Souteyrand, Tony Barnett, Jermoe Dumoulin, and Yves-Antoine Flori, eds. 2003. Economics of AIDS and Access to to HIV/AIDS Care in Developing Countries: Issues and Challenges. Paris: Collection Sciences Sociales et Sida. Themba. 2007. “Lessons from Botswana and the African Comprehensive HIV/AIDS Partnerships.” Moon, Suerie, Elodie Jambert, Michelle Childs, and Tido von Schoen-Angerer. 2011. “A win-win solution? A critical analysis of tiered pricing to improve access to medecines in developing countries.” Globalization and Health: 7:39. Moon, Suerie. 2013. “Respecting the right of access to medicines: Implications of the UN Guiding principles on business and human rights for the pharmaceutical industry.” Health and Human Rights: 15:1, 32-43. Moon, Suerie and Wolfgang Hein. 2013. Informal Norms in Global Governance: Human Rights, Intellectual Property Rules, and Access to Essential Medicines. Ashgate Publishing: Farnam. Mugyenyi, Peter, et al. 2006. “Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre access programme.” Acta Academica Supplementum, 1, pp. 216-40. Mutume, Gumisai. 2001. “AIDS Activists March Against Pharmaceutical Companies.” Third World Network. http://www.twnside.org.sg/title/against.htm. Nunn, Amy, Elize Fonseca, Francisco Bastos, Sofia Gruskin, Joshua Salomon. 2007. “Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment.” PLoS Medicine, 4:11, 1804-17.
Watal, Jayashree. 2001. “Workshop on Differential Pricing and Financing of Essential Drugs: Background Note.” WTO Secretariat. World Health Organization. 2001. “More Equitable Pricing for Essential Drugs: What do we Mean and what are the Issues?” Background paper for the WHO-WTO secretariat workshop on differential pricing and financing of essential drugs. World Health Organization. 2001b. “Report of the Workshop on Differential Pricing and Financing of Essential Drugs.” Health Organization. 2006. “Access to AIDS medicines stumbles on trade rules.” http://www.who.int/bulletin/volumes/84/5/news10506/en/#. World Health Organization. 2007. “Afro Essential Medicines Price Indicator.” World Health Organization. 2008. “Uganda edges closer to AIDS treatment for all.” www.who.int/bulletin/volumes/86/6/08-020608/en/. World Health Organization. 2013. “Global Price Reporting Mechanism.” . World Health Organization. 2013(b). “Global Report on HIV Treatment: Results, Impacts, and Opportunities.” Health Organization. 2014. “The Doha Declaration on the TRIPS Agreement and Public Health.” http://www.who.int/medicines/areas/policy/doha_declaration/en/. World Trade Organization. “Trips Agreement.” Signed 1994.. Trade Organization. 2001. “NGOs Attending the Fourth WTO Ministerial Conference, Doha, Qatar 9-13 November 2001.” . World Trade Organization. 2001. “647 Non-governmental Organisations Eligible to Attend the Doha Ministerial.” . World Trade Organization. 2001. “Doha Declaration on the TRIPS Agreement and Public Health.” . World Trade Organization. 2001. “Developing Country Group’s Paper.” . World Trade Organization. 2001. “EU’s Paper.” . World Trade Organization. 2009. “Universal Access to Antiretroviral Therapy: The Brazilian Experience.”